Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-ß in parathyroid carcinomas

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 481-492

  Juhlin, C Christofer ^a   Haglund, Felix ^a   Villablanca, Andrea ^a   Forsberg, Lars ^a   Sandelin, Kerstin ^a   Bränström, Robert ^a   Larsson, Catharina ^a   Höög, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

catenin; APC expression; Cyclin D1; GSK3 ; Parathyroid carcinoma

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MONOCLONAL ANTIBODY; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; COLON POLYPOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PARATHYROID NEOPLASMS; SENSITIVITY AND SPECIFICITY; WNT PROTEINS;

EID: 64549160727     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000173     Document Type: Article

References (43)

1. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Höög A, Heath H III, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C and Hobbs MR: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32: 676-680, 2002.
2. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H and Teh BT: HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40: 657-663, 2003.
3. Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C and Arnold A: Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349: 1722-1729, 2003.
4. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P, Miccoli P, Pinchera A and Marcocci C: Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89: 5583-5591, 2004.
5. Krebs LJ, Shattuck TM and Arnold A: HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90: 5015-5057, 2005.
6. Juhlin C, Höög A, Yakoleva T, Leibiger I, Leibiger B, Weber G, Larsson C and Villablanca A: Loss of parafibromin expression in a subset of sporadic parathyroid adenomas. Endocr Relat Cancer 13: 509-523, 2006.
7. Mosimann C, Hausmann G and Basler K: Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/ Armadillo. Cell 125: 327-341, 2006.
8. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemits S and Polakis P: Association of the APC gene product with β-catenin. Science 262: 1731-1734, 1993.
9. Su LK, Vogelstein B and Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 262: 1734-1737, 1993.
10. Van Noort M, Meeldijk J, van der Zee R, Destree O and Clevers H: Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277: 17901-17905, 2002.
11. Shane E: Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86: 485-493, 2001.
12. Rodgers SE and Perrier ND: Parathyroid carcinoma. Curr Opin Oncol 18: 16-22, 2006.
13. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H and Teh BT: Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10: 6629-6637, 2004.
14. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM and Marsh DJ: Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30: 1140-1149, 2006.
15. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A and Marcocci C: Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156: 547-554, 2007.
16. Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenström J, Forsberg L, Bränström R, Obara T, Arnold A, Larsson C and Höög A: Parafibromin immunoreactivity - its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14: 501-512, 2007.
17. Shamlal M and DeLellis RA: In response. Adv Anat Pathol 15: 179-180, 2008.
18. Tominaga Y, Tsuzuki T, Matsuoka S, Uno N, Sato T, Shimabukuro S, Goto N, Nagasaka T and Uchida K: Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 32: 815-821, 2008.
19. Bondeson L, Sandelin K and Grimelius L: Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 17: 820-829, 1993.
20. Farnebo F, Auer G, Farnebo L-O, Teh BT, Twigg S, Aspenbladh U, Thompson NW, Grimelius L, Larsson C and Sandelin K: Evaluation of retinoblastoma and Ki-67 as diagnostic markers in benign and malignant parathyroid disease. World J Surg 23: 68-74, 1999.
21. DeLellis RA, Lloyd RV, Heitz PU and Eng C: Pathology and genetics of the tumours of endocrine organs. In: WHO Classification of Tumours. DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds). IARC Press, Lyon, pp124-127, 2006.
22. Lu M, Forsberg L, Höög A, Juhlin CC, Vukojevic V, Larsson C, Conigrave AD, Delbridge LW, Gill A, Bark C, Farnebo LO and Bränström R: Heterogeneous expression of SNARE proteins SNAP-23, SNAP-25, Syntaxin1 and VAMP in human parathyroid tissue. Mol Cell Endocrinol 287: 72-80, 2008.
23. Kraus C, Reina-Sanchez J, Suleková Z and Ballhausen WG: Immunochemical identification of novel high-molecular-weight protein isoforms of the adenomatous polyposis coli (APC) gene. Int J Cancer 65: 383-388, 1996.
24. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L and Robertson M: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589-600, 1991.
25. Hanson CA and Miller JR: Non-traditional roles for the adenomatous polyposis coli (APC) tumor suppressor protein. Gene 361: 1-12, 2005.
26. Björklund P, Åkerström G and Westin G: Accumulation of nonphosphorylated β-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab 92: 338-344, 2007.
27. Kytölä S, Farnebo F, Obara T, Isola J, Grimelius L, Farnebo L-O, Sandelin K and Larsson C: Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 157: 579-586, 2000.
28. Segditsas S and Tomlinson I: Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25: 7531-7537, 2006.
29. Schneider NR, Cubilla AL and Chaganti RS: Association of endocrine neoplasia with multiple polyposis of the colon. Cancer 51: 1171-1175, 1983.
30. Offerhaus GJ, Levin LS, Giardiello FM, Krush AJ, Welsch SB, Booker SV, Hasler JF, McKusick VA, Yardley JH and Hamilton SR: Occult radiopaque jaw lesions in familial adenomatous polyposis coli and hereditary nonpolyposis colorectal cancer. Gastroenterology 93: 490-947, 1987.
31. Jackson CE, Norum RA, Boyd SB, Talpos GB, Wilson SD, Taggart RT and Mallette LE: Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108: 1006-1012, 1990.
32. Karim R, Tse G, Putti T, Scolyer R and Lee S: The significance of the Wnt pathway in the pathology of human cancers. Pathology 36: 120-128, 2004.
33. Björklund P, Lindberg D, Åkerström G and Westin G: Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol Cancer 7: 53, 2008.
34. Ikeda S, Ishizaki Y, Shimizu Y, Fujimori M, Ojima Y, Okajima M, Sugino K and Asahara T: Immunohistochemistry of cyclin D1 and beta-catenin, and mutational analysis of exon 3 of beta-catenin gene in parathyroid adenomas. Int J Oncol 20: 463-466, 2002.
35. Costa-Guda J and Arnold A: Absence of stabilizing mutations of beta-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. J Clin Endocrinol Metab 92: 1564-1566, 2007.
36. Bordonaro M, Lazarova DL and Sartorelli AC: Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer? Oncol Res 17: 1-9, 2008.
37. Qian J, Sarnaik AA, Bonney TM, Keirsey J, Combs KA, Steigerwald K, Acharya S, Behbehani GK, Barton MC, Lowy AM and Groden J: The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology 135: 152-162, 2008.
38. Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG and Choi EJ: Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem 278: 13995-14001, 2003.
39. Huang W, Chang HY, Fei T, Wu H and Chen YG: GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 26: 2471-2482, 2007.
40. Iihara M, Okamoto T, Suzuki R, Kawamata A, Nishikawa T, Kobayashi M and Obara T: Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery 142: 936-943, 2007.
41. Giardiello FM, Hamilton SR, Krush AJ, Booker S, Jen J, Giardiello FM, Hamilton SR, Vogelstein B and Kinzler KW: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993.
42. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
43. Eisinger AL, Nadauld LD, Shelton DN, Prescott SM, Stafforini DM and Jones DA: Retinoic acid inhibits β-catenin through suppression of cox-2: a role for truncated adenomatous polyposis coli. J Biol Chem 282: 29394-29400, 2007.